Swiss biotechnology company Lonza Group AG (Lonxa) (SWX: LONN) has agreed with British pharmaceutical company AstraZeneca Plc (STO: AZN) (LON: AZN) to make AZD7442, an experimental combination of two antibodies that may be used to prevent and treat COVID-19, Reuters news agency reported on Friday.
According to Lonxa, AZD7442 is in Phase I clinical studies and AstraZeneca plans to advance the combination into Phase III trials in the coming weeks.
Lonza will manufacture drug substance for AZD7442 at its facilities in the US.
These operations are expected to commence in the first half of 2021.
Genentech reports first oral SERD to improve invasive disease-free survival in early breast cancer
Biotheryx completes enrolment in ongoing Phase 1a trial of BTX-9341 for HR+/HER2- breast cancer
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Pulmonary Fibrosis Foundation Launches New Five-Year Strategy: The PFF is ME
Acumen Pharmaceuticals begins open-label extension of Phase 2 Alzheimer's study
Incyte receives positive CHMP opinion for Minjuvi in relapsed or refractory follicular lymphoma
BioInvent secures EMA positive opinion for Orphan Drug Designation of BI-1808 in CTCL
IXICO wins GBP3.5m global Phase 3 Huntington's Disease trial contract
Japan's Ministry of Health, Labor and Welfare accepts Lundbeck's NDA for Vyepti (eptinezumab)
BodyLogicMD supports recommendation to remove black box warnings on certain forms of oestrogen
Fondazione Telethon reports positive opinion for Waskyra marketing authorisation in Europe
Cognision partners with Kynexis for use of COGNISION system in schizophrenia trial
CHMP issues positive opinion for DAWNZERA in hereditary angioedema